CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 159 enrolled
Drug / intervention
Haloperidol, Risperidone (drug)drug
Likely dose
Haloperidol, Risperidone (drug) 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00159081
NCT00159081Phase 4Completed
CompareCT.gov

One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia

Heinrich-Heine University, Duesseldorf·interventional·Posted Sep 12, 2005·Updated Feb 7, 2008

In Brief

A Phase 4 clinical trial evaluating Haloperidol, Risperidone (drug) for Schizophrenia. Completed, enrolled 159 participants across 1 site.

Detailed Summary

Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesGermany
CollaboratorsGerman Federal Ministry of Education and Research, German Research Network On Schizophrenia, Janssen-Cilag Ltd., University of Bonn, Humboldt-Universität zu Berlin, University of München, University of Göttingen, University of Cologne, Mainz University, University Hospital Tuebingen, Universität Duisburg-Essen, University of Mannheim, University of Jena, Martin-Luther-Universität Halle-Wittenberg, RWTH Aachen University, University of Wuerzburg

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartNov 1, 2000
Primary CompletionJun 1, 2005
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 20.8 years ago

Interventions

Haloperidol, Risperidone (drug)drug

targeted dose of 2-4 mg/day over 1 year